U.S. Missile Stockpiles Decrease, FDA Considers mRNA Flu Vaccine

The U.S. Army's missile stockpiles have decreased, and officials estimate replenishment could require several years. This reduction in inventory comes as the Food and Drug Administration (FDA) considers approving a new flu vaccine that incorporates messenger RNA (mRNA) technology.

Defense officials have indicated that current U.S. Army missile reserves have reached levels that necessitate a prolonged period for restoration. They project that rebuilding these stockpiles to previous capacities will take multiple years.

Separately, the FDA is evaluating a flu vaccine developed with mRNA technology. This assessment will determine whether the vaccine meets regulatory standards for public use. The outcome of the FDA's review will dictate its availability.